MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is phenotypically heterogeneous with a highly unstable genome and provides few common therapeutic targets. We found that MCL1, Cofilin1 (CFL1) and SRC mRNA were highly expressed by a wide range of these cancers, su...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Oncogene Ročník 39; číslo 8; s. 1821 - 1829
Hlavní autoři:	Castillo, Lesley, Young, Adelaide I J, Mawson, Amanda, Schafranek, Pia, Steinmann, Angela M, Nessem, Danielle, Parkin, Ashleigh, Johns, Amber, Chou, Angela, Law, Andrew M K, Lucas, Morghan C, Murphy, Kendelle J, Deng, Niantao, Gallego-Ortega, David, Caldon, Catherine E, Timpson, Paul, Pajic, Marina, Ormandy, Christopher J, Oakes, Samantha R
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Nature Publishing Group 01.02.2020
Témata:	Adenocarcinoma Adenocarcinoma - pathology Animal models Cell culture Cell Line, Tumor Cell viability Cytoskeleton Dasatinib - pharmacology Drug Synergism Enzyme inhibitors Gene expression Genomes Humans Immunohistochemistry Invasiveness Liver cancer Mcl-1 protein Metastases Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors Neoplasm Invasiveness Pancreatic cancer Pancreatic Neoplasms - pathology Src protein Therapeutic applications Therapeutic targets Xenografts
ISSN:	0950-9232, 1476-5594, 1476-5594
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!